PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Provincial Cancer Hospital

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Advanced Solid Tumor

Treatments: Drug: CVL218

Study type: Interventional

Funder types: Other

Identifiers

NCT06078670

CVL218-1003

Details and patient eligibility

About

This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors. It focuses on assessing the safety, tolerability, and pharmacokinetic profile of a three-drug combination regimen comprising albumin-bound paclitaxel injection (Kealil), paclitaxel injection (Taxol), and Fuquinitinib capsule (Aiutec, Fruquintinib).

Full description

This Phase Ib/II clinical study is designed to determine the recommended Phase II dosage of the combination therapy and its initial efficacy. The study consists of two phases: an exploratory phase (Ib) and an extended phase (II), each divided into three stages: the screening period, treatment period, and follow-up period.

The screening period occurs 28 days prior to the first dose administration. Three parallel queues were organized, with Phase Ib enrolling 3-6 participants per dose level cohort and Phase II enrolling approximately 20 participants per cohort.

In Phase II, subjects must demonstrate evidence of deleterious HRD gene variants (such as BRCA1, BRCA2, PALB2, ATM, CHEK2 variants) or a positive PD-L1 molecular expression level combined score (CPS) of ≥1. Additionally, Phase II participants are required to consent to the provision of sufficient archived or fresh tumor tissue and blood samples for biomarker analysis in the central laboratory, including determination of HRD gene mutation status and PD-L1 expression level (details in Section 7.4).

During the treatment period, the three cohorts received CVL218 orally (PO) in combination with a fixed dose of either terriplizumab injection (Toripalimab) or Sintilimab injection (Darbersol, Sintilimab). Additionally, they were administered albumin-bound paclitaxel injection (Kealil)/paclitaxel injection (Taxol)/Fuquintinib capsule (Aiutec, Fruquintinib).

CVL218 was administered at two dose levels, ranging from low to high (500 mg, 700 mg), twice daily (BID), during the exploration of cohorts in Phase Ib. After determining the recommended dose of CVL218 in all cohorts of the three-drug combination, this dose level was maintained during Phase II. When CVL218 and the combination were administered on the same day, CVL218 was given first.

Enrollment: 96 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Patients between the ages of 18 and 75 (including those aged 18 and 75, and those over 60 years old should not suffer from more than 3 complications of heart, lung, liver and kidney function at the same time), regardless of gender.

  2. Patients with locally advanced or metastatic advanced solid tumors confirmed by histology or cytology (including but not limited to triple-negative breast cancer, gastric cancer, colorectal cancer); Patients with ≤1 line of standard treatment failure (disease progression after treatment or intolerability of toxic side effects of treatment), or no standard treatment, or unable to receive standard treatment.

  3. In stage II, patients with positive PD-L1 molecular expression level combined with CPS≥1 were required to be enrolled, or there was evidence of harmful HRD gene variants (BRCA1, BRCA2, PALB2, ATM, CHEK2 variants, etc.).

Exclusion criteria

• Chemotherapy, radiotherapy, biotherapy and endocrinology were received within 4 weeks before the first administration

Treatment, immunotherapy and other antitumor drugs, except the following:

Nitrosourea or mitomycin C within 6 weeks before first use of the study drug;

Oral fluorouracil and small molecule targeted drugs are used before first investigational drugs

2 weeks or within 5 half-lives of the drug, whichever is longer;

Traditional Chinese medicines with anti-tumor indications were used within 2 weeks before the first use of study drugs.

2. Received other investigational drugs or treatments that are not on the market within 4 weeks prior to initial administration

Therapy.

3. Received major organ surgery (excluding puncture) within 4 weeks prior to initial administration

Biopsy) or significant trauma.

4. Received systemic glucocorticoids (strong) within 14 days prior to initial administration

Pine > 10mg/ day or equivalent dose of similar drugs) or other immunosuppressant

Treatment;

Except in the following cases: topical, ocular, intraarticular, intranasal, and inhalation

Type I glucocorticoid therapy; Short-term use of corticosteroids for prophylactic treatment (eg to prevent contrast allergy).

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

96 participants in 3 patient groups

Triple Negative Breast Cancer

Experimental group

Description:

CVL218+Toripalimab+Paclitaxel For Injection (Albumin Bound)

Treatment:

Drug: CVL218

Stomach cancer

Experimental group

Description:

CVL218+Sintilimab+Paclitaxel Injection

Treatment:

Drug: CVL218

Intestinal cancer

Experimental group

Description:

CVL218+Sintilimab+Fruquintinib

Treatment:

Drug: CVL218